Plasma and plasma derivatives in therapeutic plasmapheresis

Transfusion

Volumn 52, Issue SUPPL. 1, 2012, Pages

  McLeod, Bruce C ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; HUMAN SERUM ALBUMIN; PLASMA PROTEIN;

ALLERGIC REACTION; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD COMPONENT THERAPY; BLOOD GROUP TYPING; FEVER; HUMAN; PASTEURIZATION; PLASMA TRANSFUSION; PLASMAPHERESIS; PROTEIN DEFICIENCY; SUPERNATANT; THAWING; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRUS INACTIVATION;

BLOOD COMPONENT TRANSFUSION; BLOOD DONORS; FACTOR VIII; FIBRINOGEN; HUMANS; PLASMA; PLASMA EXCHANGE; PLASMAPHERESIS; SERUM ALBUMIN;

EID: 84861141123     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03623.x     Document Type: Article

References (47)

1. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH,; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25: 83-177.
2. Tullis JL,. Albumin 1. Background and use. JAMA 1977; 237: 355-60.
3. Finlayson JS,. Albumin products. Semin Thromb Hemost 1980; 6: 85-120.
4. Matejtschuk P, Dash CH, Gascoigne EW,. Production of human albumin solutions: a continually developing colloid. Br J Anaesth 2000; 85: 887-95.
5. Chopek M, McCullough J,. Protein and biochemical changes during plasma exchange. In:, Berkman EM, Umlas J, editors. Therapeutic hemapheresis. Washington, DC: American Association of Blood Banks; 1980. p. 13-52.
6. Weinstein R,. Basic principles of therapeutic blood exchange. In:, McLeod BC, Weinstein R, Winters JL, Szczepiorkowski ZM, editors. Apheresis: principles and practice. 3rd ed. Bethesda (MD): American Association of Blood Banks Press; 2010. p. 269-94.
7. Peters T,. Serum albumin. In:, Putnam FW, editor. The plasma proteins. Vol. 1. 2nd ed. New York: Academic Press; 1975. p. 133-81.
8. Putnam FW,. Transferrin. In:, Putnam FW, editor. The plasma proteins. Vol. 1. 2nd ed. New York: Academic Press; 1975. p. 266-316.
9. Monroe DM, Hoffman M, Roberts HR,. Molecular biology and biochemistry of the coagulation factors and pathways of hemostasis. In:, Kaushansky K, Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Prchal JT, editors. Williams hematology. 8th ed. New York: McGraw-Hill Medical; 2010. p. 1815-44.
10. McClelland DLC,. Safety of human albumin as a constituent of biologic therapeutic products. Transfusion 1998; 38: 690-9.
11. Tabor E,. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999; 39: 1160-8.
12. Baxter Healthcare Corporation. Entry for buminate. Physician's desk reference. 65th ed. p. 803-4. Montvale (NJ): PDR Network LLC; 2011.
13. Stafford CT, Lobel SA, Fruge BC, Moffitt JE, Hoff RG, Fadel HE,. Anaphylaxis to human serum albumin. Ann Allergy 1988; 61: 85-8.
14. Pool M, McLeod BC,. Pyrogen reactions to human serum albumin in plasma exchange. J Clin Apher 1995; 10: 81-4.
15. Pierce LR, Gaines A, Finlayson JS, Varricchio F, Epstein J,. Hemolysis and acute renal failure due to the administration of albumin diluted in sterile water. Transfusion 1999; 39: 110-1.
16. Vincent J-L, Wilkes MM, Navickis RJ,. Safety of human albumin - serious events reported worldwide in 1998-2000. Br J Anaesth 2003; 91: 625-30.
17. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomized controlled trials. Brit Med J 1998; 317: 235-40.
18. Wilkes MM, Navickis RJ,. Patient survival after human albumin administration: a meta-analysis of randomized, controlled trials. Ann Intern Med 2001; 135: 149-64.
19. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R,; SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350: 2247-56.
20. Owen HG, Brecher ME,. Atypical reactions associated with the use of angiotensin-converting enzyme inhibitors with apheresis. Transfusion 1994; 34: 891-4.
21. Verresen L, Waer M, Vanrenterghem Y, Michielsen P,. Angiotensin- converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis. Lancet 1990; 316: 1360-2.
22. Imré Corporation. Special PMA Supplement P850020, 3/12/93. 1993.
23. Olbricht CJ, Schaumann D, Fischer DL,. Anaphylactoid reactions, LDL apheresis with dextran sulphate, and ACE inhibitors. Lancet 1995; 340: 908-9.
24. Alving BM, Hojima Y, Pisano JJ, Mason BL, Buckingham RE Jr, Mozen MM, Finlayson JS., Hypotension associated with prekallikrein activator (Hageman-factor fragments) in plasma protein fraction. N Engl J Med 1978; 299: 66-70.
25. Silberstein LE, Naryshkin S, Haddad JJ, Strauss JF III,. Calcium homostasis during therapeutic plasma exchange. Transfusion 1986; 26: 151-5.
26. Couriel D, Weinstein R,. Complications of therapeutic plasma exchange: a recent assessment. J Clin Apher 1994; 9: 1-5.
27. Weinstein R,. Prevention of citrate reactions during therapeutic plasma exchange by constant infusion of calcium gluconate with the return fluid. J Clin Apher 1996; 11: 204-10.
28. Goss GA, Weinstein R,. Pentastarch as partial replacement fluid for therapeutic plasma exchange: effect on plasma proteins, adverse events during treatment, and serum ionized calcium. J Clin Apher 1999; 14: 114-21.
29. McLeod BC, Price TH, Owen H, Price TH, Randels MJ, Smith JW,. Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion 1999; 39: 282-8.
30. Norda R, Berseus O, Stegmayr B,. Adverse events and problems in therapeutic hemapheresis. A report from the Swedish registry. Transfus Apher Sci 2001; 25: 33-41.
31. Korach JM, Guillevin L, Pettipas D, Berger P, Chillet P,. Apheresis registry in France: indications, techniques and complications. Ther Apher 2000; 4: 207-10.
32. Shemin D, Briggs D, Greenan M,. Complications of therapeutic plasma exchange: a prospective study of 1727 procedures. J Clin Apher 2007; 22: 270-6.
33. Roback JD, editor. Technical manual. 17th ed. p. 204-5. Bethesda: American Association of Blood Banks; 2011.
34. Scott E, Puca K, Heraly J, Gottschall J, Friedman K,. Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6°C storage. Transfusion 2009; 49: 1584-91.
35. Raphael JC,; for the French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Efficacy of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987; 22: 753-61.
36. Pearl RG, Rosenthal MH,. Metabolic alkalosis due to plasmapheresis. Am J Med 1985; 79: 391-3.
37. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA,. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-7.
38. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B,. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
39. Tsai H-M, Lian EC-Y,. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94.
40. Winters JL, Pineda AA, McLeod BC, Grima KM,. Therapeutic apheresis in renal and metabolic disorders. J Clin Apher 2000; 15: 53-73.
41. Moake JL,. Thrombotic thrombocytopenic purpura. Thromb Haemost 1995; 74: 240-5.
42. Michael M, Elliot EJ, Craig JC, Ridley G, Hodson EM,. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009; 53: 259-72.
43. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW,. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992; 79: 826-31.
44. McLeod B, Gregory SA,. Solvent/detergent plasma replacement in a highly plasma allergic patient with TTP. J Clin Apher 2001; 16: 98. (abstract).
45. Pereira A,. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion 1999; 39: 479-87.
46. Flamholz R, Jeon HR, Baron JM, Baron BW,. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses? J Clin Apher 2000; 15: 169-72.
47. de Jonge J, Groenland TH, Metselaar HJ, IJzermans JN, van Vliet HH, Visser L, Tilanus HW,. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma. Anesth Anal 2002; 94: 1127-31.